RT Journal Article
SR Electronic
T1 Cumulative COVID-19 incidence indicators should account for the population-at-risk dynamics
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.10.18.22281225
DO 10.1101/2022.10.18.22281225
A1 Pere Masjuan
A1 Sergi Trias-Llimós
A1 Camilo Rojas
A1 Arul Prakash
A1 Pedro Gullón
A1 Aurelio Tobias
A1 Antonio López-Gay
YR 2022
UL http://medrxiv.org/content/early/2022/10/20/2022.10.18.22281225.abstract
AB Risk estimators for COVID-19 propagation based on the incidence rate of new cases can be misleading as they usually fail to account for the fraction of population immunized by infection or vaccination.This misconception yields different incidence rates, as we illustrate using the daily number of COVID-19 reported cases in Spain during the pre-vaccine period, between 15/01/2020 and 11/07/2021. An increase in the incidence rate of about 7% is found when properly accounting for the population at risk. Our results demonstrate that accounting for dynamic changes to the immunized fraction of the population is necessary for accurate risk estimation. We hope that our findings can lead to more effective strategies for pandemic response.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors affiliated to CED acknowledge the support of the CERCA institution, Centres de Recerca de Catalunya. AL acknowledges the support from the Talent Research Program (Universitat Autonoma de Barcelona). PM, CR, and AP acknowledge the support from the Ajuntament de Barcelona. STL acknowledges research funding from the Juan de la Cierva-Formacion (Spanish Ministry of Science and Innovation, FJC-2019-039314-I). PG is supported by Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union (PI18/00782 and PI21/01868) and by Comunidad de Madrid (Linea de actuacion Estimulo a la Investigacion de Jovenes Doctores, CM/JIN/2021-028). AT was supported by MCIN/AEI/10.13039/501100011033 (grant CEX2018-000794-S).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article come from the Centro Nacional de Epidemiologia and the Instituto de Salud Carlos III, and are available at https://rubenfcasal.github.io/COVID-19/